Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $15.00

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) had its target price increased by HC Wainwright from $9.00 to $15.00 in a research report report published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, JonesTrading began coverage on Armata Pharmaceuticals in a report on Monday, January 5th. They issued a “buy” rating and a $15.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $15.00.

Armata Pharmaceuticals Trading Down 10.4%

Shares of NYSEAMERICAN:ARMP opened at $10.63 on Monday. The business has a 50 day moving average of $7.14 and a two-hundred day moving average of $5.32. The company has a market capitalization of $387.04 million, a PE ratio of -6.56 and a beta of 1.42. Armata Pharmaceuticals has a 12-month low of $0.90 and a 12-month high of $16.34.

Hedge Funds Weigh In On Armata Pharmaceuticals

A number of hedge funds have recently modified their holdings of ARMP. Jane Street Group LLC purchased a new stake in Armata Pharmaceuticals in the 4th quarter valued at about $108,000. Millennium Management LLC purchased a new position in Armata Pharmaceuticals during the fourth quarter worth about $164,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Armata Pharmaceuticals during the fourth quarter valued at about $177,000. SeaCrest Wealth Management LLC raised its stake in shares of Armata Pharmaceuticals by 17.3% in the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock valued at $274,000 after acquiring an additional 6,034 shares during the period. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Armata Pharmaceuticals in the 4th quarter valued at $284,000. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.